Arcus Biosciences, Inc.
RCUS
$9.34
-$0.20-2.10%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 120.51% | 119.17% | 104.13% | 99.16% | 4.46% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 120.51% | 119.17% | 104.13% | 99.16% | 4.46% |
| Cost of Revenue | 29.43% | 32.94% | 19.03% | -4.87% | -7.99% |
| Gross Profit | 42.57% | 45.45% | 62.70% | 70.37% | 15.91% |
| SG&A Expenses | 2.56% | 4.31% | 8.04% | 8.18% | 12.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.29% | 26.64% | 19.82% | 16.51% | 16.58% |
| Operating Income | 8.82% | 7.74% | 12.78% | 16.39% | -21.43% |
| Income Before Tax | 6.31% | 6.60% | 13.38% | 18.05% | -13.16% |
| Income Tax Expenses | -83.33% | -80.00% | 0.00% | 100.00% | 500.00% |
| Earnings from Continuing Operations | 7.82% | 7.85% | 13.24% | 17.20% | -14.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.82% | 7.85% | 13.24% | 17.20% | -14.98% |
| EBIT | 8.82% | 7.74% | 12.78% | 16.39% | -21.43% |
| EBITDA | 9.64% | 9.15% | 13.73% | 17.47% | -21.17% |
| EPS Basic | 25.36% | 21.06% | 21.42% | 19.46% | -11.88% |
| Normalized Basic EPS | 29.85% | 25.94% | 27.56% | 26.35% | -10.11% |
| EPS Diluted | 25.36% | 21.09% | 21.45% | 19.49% | -11.83% |
| Normalized Diluted EPS | 29.85% | 25.94% | 27.56% | 26.35% | -10.11% |
| Average Basic Shares Outstanding | 21.84% | 17.14% | 12.34% | 6.70% | 2.78% |
| Average Diluted Shares Outstanding | 21.84% | 17.14% | 12.34% | 6.70% | 2.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
